---

Article 1 — Hao Z et al. — Peripheral blood ML model for myelofibrosis

PMID: 42203504 | Triage Score: 8 | 🟢 NEAR_TERM_IMPLEMENTABLE

Dimension	Score	Rationale
Scientific Novelty	7	Interpretable SVM on peripheral blood parameters for non-invasive MF staging is genuinely useful; SHAP-based mechanistic validation of IL-1β adds novelty beyond prior ML-MPN models
Clinical Relevance	8	Directly addresses a real, recurring clinical burden — serial bone marrow biopsies in MPN patients; AUC 0.916 in external validation is strong for a 3-variable model
Population Reach	5	JAK2 V617F-positive MPNs — moderate-sized rare disease population; ~1–2/100,000 prevalence but monitoring burden is high and ongoing
Implementation Speed	7	Three peripheral blood parameters (Hgb, IL-1β, age) are clinically accessible; requires IL-1β assay availability and prospective calibration across centers
Evidence Strength	7	Multicentre prospective design with external validation (n=92); LASSO+Boruta feature selection; abstract-only limits full critique but design is methodologically sound

Key Quantitative Result: AUC 0.916 (95% CI 0.83–0.99) in external validation; IL-1β reversed by ruxolitinib/pegIFN-α but not hydroxyurea.

External Validation: Yes — independent external validation cohort (n=92) across multicentre design (China + US site).

Main Limitation: Pilot/proof-of-concept stage; bone marrow biopsy remains reference standard; IL-1β assay not universally available in routine hematology workup; abstract-only review.

Equity Implications: Reduces dependency on invasive biopsy, potentially benefiting patients in lower-resource settings where biopsy access/expertise is limited. IL-1β assay cost could be a barrier in resource-constrained environments. No sex/race stratification data available from abstract.

Evidence Maturity: Validated ✓ (confirmed)

---

Article 2 — Banda K et al. — HRDetect in Tubo-ovarian Carcinoma

PMID: 42201779 | Triage Score: 8 | 🟠 NOVEL_TREATMENT

Dimension	Score	Rationale
Scientific Novelty	8	Redefinition of HRD landscape beyond binary HRD/HRP — the 23.2% intermediate category and 11 rearrangement signature clusters are genuinely new stratification layers with immediate research implications
Clinical Relevance	9	54% vs 22.5% response rate to rucaparib; significantly improved PFS (HR 0.44) — these are meaningful, practice-informing effect sizes for PARPi prescribing decisions
Population Reach	6	Ovarian cancer is relatively common (~14/100,000); HER2 amplified/advanced-stage subpopulation is substantial; WGS requirement narrows immediate reach
Implementation Speed	5	WGS-based approach requires infrastructure and cost beyond routine clinical NGS panels; reimbursement pathway for WGS-based HRDetect is not yet established at scale
Evidence Strength	8	WGS cohort (n=185) with independent ARIEL2 trial validation (n=77); Nik-Zainal/Swisher authorship; matched tumor-normal pairs; published in CCR

Key Quantitative Result: OS: 6.2 vs 4.1 years (HR 0.60, p=0.007); PFS: 11.1 vs 7.1 months (HR 0.44, p=0.03); response rate 54% vs 22.5%.

External Validation: Yes — independent validation in ARIEL2 rucaparib trial cohort (n=77).

Main Limitation: WGS requirement is a major practical barrier vs. routine tissue NGS; abstract-only review; intermediate category clinical management implications remain undefined.

Equity Implications: WGS-based testing disproportionately benefits patients at well-resourced academic centers. Community oncology and LMIC patients are underserved. BRCA-negative patients in the intermediate category represent a population currently denied PARPi access who may benefit — a potential equity gain if clinically validated.

Evidence Maturity: Validated ✓ (confirmed)

---

Article 3 — Liu Z et al. — DHCC CRISPR/Cas14a ctDNA detection

PMID: 42202254 | Triage Score: 7 | 🔴 EARLY_CANCER_DETECTION

Dimension	Score	Rationale
Scientific Novelty	9	0.002% VAF detection — 250-fold improvement over prior Cas14a systems — using dual hairpin architecture is a meaningful technical breakthrough; running on standard qPCR equipment is a key democratizing innovation
Clinical Relevance	5	Platform-level discovery; clinical validation is extremely limited (n=22, one mutation locus); not yet practice-informing but targets a real sensitivity gap
Population Reach	7	ctDNA/liquid biopsy is applicable across essentially all solid tumor types; EGFR-mutant NSCLC alone is a large target population; broader applicability is the key promise
Implementation Speed	4	Requires further clinical validation at scale; regulatory pathway (FDA/CE-IVD) is multi-year; no current clinical deployment
Evidence Strength	5	Analytically rigorous (LOD well-characterized); clinical cohort n=22 is insufficient for clinical evidence grading; 100% ddPCR concordance is promising but single-site/single mutation

Key Quantitative Result: LOD = 0.002% VAF; 250-fold sensitivity gain over prior Cas14a; 100% concordance with ddPCR (n=22, EGFR L858R).

External Validation: None — single-site analytical development study.

Main Limitation: Clinical cohort n=22, single mutation (EGFR L858R), single site. Four mutations tested analytically only. Analytical performance ≠ clinical utility.

Equity Implications: Operating on standard qPCR equipment rather than specialized ddPCR platforms is the key equity advantage — potentially applicable in LMIC clinical labs. Cost of CRISPR reagents and accessibility in low-resource settings remain unknown.

Evidence Maturity: Exploratory ✓ (confirmed)

---

Article 4 — Atiq S et al. — Emerging Biomarkers for HGSOC Early Detection

PMID: 42202925 | Triage Score: 6 | 🔴 EARLY_CANCER_DETECTION

Dimension	Score	Rationale
Scientific Novelty	4	Review synthesizes existing literature; methylation-based liquid biopsy as a leading approach is already established consensus — no new primary data
Clinical Relevance	6	Ovarian cancer early detection remains an urgent unmet need with no validated screening test; review provides useful clinical synthesis even without new data
Population Reach	7	HGSOC accounts for ~70% of ovarian cancer deaths; global population-level screening question with high mortality impact
Implementation Speed	3	No existing test to implement; field is still building foundational evidence; review confirms this
Evidence Strength	4	Review/narrative design; medium classification confidence; no primary data contributed

Key Quantitative Result: None (review article).

External Validation: N/A.

Main Limitation: No primary data; narrative components may introduce selection bias; abstract-only.

Equity Implications: Explicitly notes validation in diverse populations as a critical gap — this is the central equity concern. Current biomarker studies are heavily skewed toward European-ancestry populations, limiting generalizability.

Evidence Maturity: Exploratory ✓ (confirmed)

---

Article 5 — Matsubara Y et al. — ctDNA profiling in HER2-amplified mCRC

PMID: 42202492 | Triage Score: 6 | 🟠 NOVEL_TREATMENT

Dimension	Score	Rationale
Scientific Novelty	7	0% objective response in ctDNA-positive resistance alteration group is a clinically striking and actionable finding; defining prior anti-EGFR as an independent negative predictor adds precision to patient selection
Clinical Relevance	8	Directly guides dual HER2 therapy prescribing decisions — a 0% vs 31.3% response rate has immediate clinical decision impact for molecular tumor boards
Population Reach	4	HER2-amplified mCRC is ~3-5% of CRC; RAS WT subset further limits population but represents a high-unmet-need group
Implementation Speed	6	ctDNA profiling is increasingly available; this framework integrates existing test (ctDNA) with clinical history — implementation is conceptually straightforward
Evidence Strength	6	Integrated prospective trial analysis (TRIUMPH + MyPathway) is a strength; n=66 with ctDNA data is a significant limitation; abstract-only

Key Quantitative Result: Prior anti-EGFR: OS 10.9 vs 19.7 months (HR 2.01); ctDNA resistance alteration: 0% ORR vs 31.3%, OS 7.6 vs 16.5 months (HR 2.15).

External Validation: Cross-trial validation (TRIUMPH Japan + MyPathway US) provides geographic/population diversity.

Main Limitation: n=66 — underpowered for robust multivariable analysis; retrospective ctDNA analysis within prospective trials; abstract-only.

Equity Implications: Both TRIUMPH (Japan) and MyPathway (US) populations — better geographic diversity than single-country studies. ctDNA profiling access may limit implementation in resource-limited settings.

Evidence Maturity: Validated ✓ (confirmed, but cautious given small n)

---

Article 6 — Zhang J et al. — PRINCE/Little Prince controlled genome editing

PMID: 42202045 | Triage Score: 5 | 🟠 NOVEL_TREATMENT

Dimension	Score	Rationale
Scientific Novelty	9	Small-molecule-inducible, single-AAV genome editing with 2-year sustained temporal precision and dramatically reduced off-target events is a landmark preclinical achievement in gene therapy safety engineering
Clinical Relevance	4	Non-human/mixed species cap applied; meaningful therapeutic correction in humanized mouse models for two diseases is encouraging; no human data
Population Reach	6	Platform applicable to broad monogenic disease space (hypercholesterolemia is common; AMD is a major cause of blindness); gene therapy addresses diseases with very high unmet need
Implementation Speed	2	Preclinical stage; IND-enabling studies, first-in-human Phase 1, and regulatory pathway are years away
Evidence Strength	4	In vitro + humanized mouse model; 2-year in vitro temporal data is impressive; mixed species cap; abstract-only; no human safety/efficacy data

Key Quantitative Result: 45–47% LDL/total cholesterol reduction; neovascular AMD lesion reduction p<0.0001; dramatically reduced off-target events over 2 years vs. constitutive editors.

External Validation: None — single-group preclinical proof-of-concept.

Main Limitation: No human data; humanized mouse models have known translational limitations; off-target quantification method not assessable from abstract; abstract-only.

Equity Implications: Gene therapy historically benefits wealthier/higher-resource patients. Single-AAV delivery is a step toward cost reduction. Rare monogenic disease orphan drug pathway may support access. Long-term, platform could reach diseases disproportionately affecting LMIC populations (e.g., certain hemoglobinopathies).

Evidence Maturity: Exploratory ✓ (confirmed)

---

Article 7 — Deiman FE et al. — PLN Cardiomyopathy RNA Therapy

PMID: 42204136 | Triage Score: 6 | 🟠 NOVEL_TREATMENT

Dimension	Score	Rationale
Scientific Novelty	7	First phosphoproteomic characterization of PLN cardiomyopathy-specific signaling distinct from other cardiomyopathies; RNA therapy reversibility of those signatures is a meaningful translational step
Clinical Relevance	5	Mixed species; no human efficacy data; mechanistic validation in a rare disease with no disease-modifying treatment is clinically meaningful in context
Population Reach	3	PLN cardiomyopathy estimated ~1:2000 in Netherlands (Dutch founder mutation); rare globally; unmet need is very high relative to population size
Implementation Speed	2	RNA therapy concept requires IND, clinical trials; preclinical stage; ASO/siRNA identity not confirmed from abstract
Evidence Strength	4	Mixed species (human cell culture + likely animal model); medium classification confidence; abstract-only; Signal Transduct Target Ther journal quality supports signal

Key Quantitative Result: Phosphoproteomic signatures reversed by RNA therapy (quantitative details not available from abstract).

External Validation: None confirmed.

Main Limitation: Mixed species; RNA therapy identity not confirmed; abstract-only; no human trial data; small rare disease population.

Equity Implications: Rare disease with founder mutation concentrated in Dutch/Northern European population. International access to RNA therapies (ASO/siRNA) is highly unequal and cost-dependent. High-unmet-need justification strengthens orphan drug access case.

Evidence Maturity: Exploratory ✓ (confirmed)

---

Article 8 — Lin CH et al. — Thrombocytosis in Prefibrotic PMF

PMID: 42203583 | Triage Score: 5 | ⬜ STANDARD

Dimension	Score	Rationale
Scientific Novelty	4	Reinforces clinical intuition with quantitative competing-risk data; thrombocytosis as an adverse pre-PMF feature is biologically expected but the HR 7.80 magnitude is noteworthy
Clinical Relevance	6	Pre-PMF vs ET distinction is a meaningful clinical challenge; platelet count as risk stratifier is immediately applicable if validated externally
Population Reach	4	Pre-PMF is a small MPN subpopulation; limited reach but high clinical impact per patient
Implementation Speed	7	Platelet count is a standard CBC parameter — zero additional testing required; immediate implementation potential
Evidence Strength	5	21-year retrospective, single center, competing-risk methodology applied; n=350 is reasonable; abstract-only

Key Quantitative Result: Thrombocytosis in pre-PMF: adjusted HR for OS 7.80 (95% CI 1.49–40.82, p=0.015); constitutional symptoms HR 10.81; leukocytosis HR 7.69.

External Validation: None — single-center retrospective.

Main Limitation: Single-center retrospective; wide CI on HR (1.49–40.82) suggests small events in subgroup analysis; no external validation.

Equity Implications: CBC-based risk stratifier is universally accessible regardless of resource setting — strongest equity case in this batch for implementation.

Evidence Maturity: Validated (downgrade to Validated-Provisional given single-center design)

---

Article 9 — Huda TI et al. — Immunogenomics of Endemic Burkitt Lymphoma

PMID: 42203338 | Triage Score: 5 | 🟡 UNDERSERVED_POPULATION

Dimension	Score	Rationale
Scientific Novelty	5	Immunogenomics landscape for endemic Burkitt lymphoma is undercharacterized; adds molecular depth to a neglected disease area
Clinical Relevance	4	Landscape study; prognostic signatures identified but no immediate treatment implication confirmed from abstract
Population Reach	5	Sub-Saharan African pediatric population with high disease incidence; limited absolute numbers but severe unmet need
Implementation Speed	2	Exploratory immunogenomics; translation to clinical tools is multi-year
Evidence Strength	4	Retrospective genomic analysis; medium confidence; sample size unknown; lower-impact journal

Key Quantitative Result: Not quantifiable from abstract.

External Validation: None confirmed.

Main Limitation: Sample size unknown; retrospective; lower-impact journal; no direct therapeutic implication evident from abstract.

Equity Implications: One of the few articles in this batch directly focusing on a sub-Saharan African pediatric disease — high equity relevance despite preliminary evidence level.

Evidence Maturity: Exploratory ✓ (confirmed)

---

Article 10 — Zhou Q et al. — DVT Prediction After Endometrial Cancer Surgery

PMID: 42204240 | Triage Score: 6 | 🟢 NEAR_TERM_IMPLEMENTABLE

Dimension	Score	Rationale
Scientific Novelty	5	SVM with SHAP explainability for DVT in gynecologic oncology is incremental; non-linear D-dimer threshold via SHAP is the novel mechanistic insight
Clinical Relevance	6	Postoperative DVT is a common, preventable complication; web-deployed tool advances clinical usability
Population Reach	6	Endometrial cancer is one of the most common gynecologic cancers; postoperative DVT is universal surgical concern
Implementation Speed	6	Web-based tool already deployed; 4-variable model uses routine parameters; integration into EHR workflow is the remaining step
Evidence Strength	6	n=841 multi-center with external validation; retrospective design; AUC 0.828 internal / 0.819 external is solid but not exceptional

Key Quantitative Result: AUC 0.828 internal, 0.819 external validation; 4-variable model (D-dimer, age, fibrinogen, clinical stage).

External Validation: Yes — external validation cohort included.

Main Limitation: Retrospective; abstract-only; clinical utility needs prospective implementation study; web tool requires institutional integration.

Equity Implications: Web-based deployment broadens access. All 4 variables are routine — no specialized testing required. Primarily validated in Chinese patient populations; external generalizability across diverse populations requires validation.

Evidence Maturity: Validated ✓ (confirmed)

---

Article 11 — Sekar P et al. — FusionNet CNN-ViT for Diabetic Retinopathy

PMID: 42204233 | Triage Score: 5 | ⬜ STANDARD

Dimension	Score	Rationale
Scientific Novelty	4	Hybrid CNN-ViT architecture is technically incremental; benchmark dataset performance does not differentiate meaningfully from recent literature
Clinical Relevance	4	Near-ceiling benchmark accuracy has limited direct clinical meaning without prospective real-world validation
Population Reach	7	Diabetic retinopathy screening is a massive global need; >500 million people with diabetes globally
Implementation Speed	3	Benchmark-only training means prospective clinical validation, regulatory clearance, and EHR integration are all prerequisite
Evidence Strength	3	Benchmark dataset only (APTOS 2019 + Messidor-2); no prospective clinical validation; near-ceiling performance typical of DR benchmark studies without clinical translation evidence

Key Quantitative Result: 98.85% accuracy, AUC-ROC 0.981 on combined benchmark datasets.

External Validation: None in real-world clinical settings.

Main Limitation: Benchmark-only performance does not predict clinical deployment success; no prospective validation; two-author study.

Equity Implications: DR screening AI has the greatest equity potential for resource-limited settings (telemedicine, rural health), but benchmark studies without implementation data do not advance this goal yet.

Evidence Maturity: Exploratory ✓ (confirmed)

---

Article 12 — Wang Y et al. — Dapagliflozin and HRV in T2DM on GLP-1 RA

PMID: 42199788 | Triage Score: 5 | ⬜ STANDARD

Dimension	Score	Rationale
Scientific Novelty	6	Autonomic nervous system interaction between SGLT2i and GLP-1 RA combination therapy is a relatively unexplored and clinically relevant signal
Clinical Relevance	5	Combination SGLT2i+GLP-1 RA is increasingly common; HRV decline signal warrants attention but observational design prevents causal inference
Population Reach	7	SGLT2i + GLP-1 RA combination is one of the most prescribed T2DM regimens globally
Implementation Speed	3	Safety signal requiring prospective confirmation before clinical action is warranted
Evidence Strength	4	Prospective observational; sample size unknown; Frontiers in Endocrinology moderate impact; no causal inference possible

Key Quantitative Result: HRV decline associated with dapagliflozin in GLP-1 RA background therapy (quantitative magnitude not available from abstract).

External Validation: None.

Main Limitation: Observational; sample size not extractable from abstract; confounding by indication likely; clinical significance of HRV change magnitude unclear.

Equity Implications: Globally relevant combination therapy; safety monitoring signal. No equity concerns specific to this finding.

Evidence Maturity: Exploratory ✓ (confirmed)

---

Article 13 — Lampsas S et al. — Semaglutide and NAION risk meta-analysis

PMID: 42201355 | Triage Score: 6 | ⬜ STANDARD

Dimension	Score	Rationale
Scientific Novelty	5	Semaglutide-NAION signal has been discussed since 2024; meta-analysis synthesizes growing observational evidence — adds rigor but not discovery
Clinical Relevance	7	Semaglutide is among the most widely prescribed drugs globally; optic neuropathy risk has immediate prescribing and informed-consent implications
Population Reach	9	Hundreds of millions of semaglutide patients globally; even a small absolute risk translates to large population-level impact
Implementation Speed	6	If confirmed, risk disclosure and ophthalmology co-monitoring could be implemented rapidly via prescribing updates
Evidence Strength	5	Meta-analysis of observational data; number of included studies unknown from abstract; medium confidence classification; inherits observational design limitations

Key Quantitative Result: Characterizes NAION risk magnitude (specific OR/RR not available from abstract).

External Validation: Indirect — meta-analysis synthesizes multiple independent studies.

Main Limitation: Meta-analysis of predominantly observational data; confounding by indication (patients on semaglutide may have more vascular risk factors); number of studies and quality assessment not reviewable from abstract.

Equity Implications: Semaglutide access is highly unequal globally (cost/availability); patients in LMIC who do access it may have less robust ophthalmologic monitoring infrastructure.

Evidence Maturity: Exploratory ✓ (confirmed — meta-analysis of observational data)

---

Article 14 — Liu C et al. — ITSN1-ALK Fusion in PDAC with Alectinib

PMID: 42203742 | Triage Score: 4 | ⚪ PROMISING_PRELIMINARY

Dimension	Score	Rationale
Scientific Novelty	8	First reported ITSN1-ALK fusion in PDAC; 19-month PFS greatly exceeds prior ALK fusion GI cancer benchmarks — a potentially important hypothesis-generating case
Clinical Relevance	5	Single case, but the implication — that broad molecular profiling in KRAS-wildtype PDAC can identify actionable fusions — is immediately relevant to molecular tumor board practice
Population Reach	3	KRAS-wildtype PDAC (~5–10% of PDAC) with ALK fusion is extremely rare; very small population but devastatingly poor prognosis
Implementation Speed	5	ALK inhibitor (alectinib) is already approved; the barrier is fusion detection through comprehensive NGS — increasingly available but not universal
Evidence Strength	2	Single case report; highest-novelty, lowest-evidence design; no generalizability; case report design cap applies

Key Quantitative Result: 19-month PFS (vs ~5 months benchmark for ALK fusion GI cancers); CA19-9 normalization; alive at Month 29.

External Validation: None.

Main Limitation: n=1; no causal proof; publication bias toward positive outcomes in case reports.

Equity Implications: Actionability requires comprehensive NGS — access is unequal. The lesson (profile KRAS-wildtype PDAC broadly) is most impactful at academic centers with molecular tumor boards.

Evidence Maturity: Exploratory ✓ (confirmed)

---

Article 15 — Plaza-Clar R et al. — Alpha-Synuclein Seed Amplification Assay Comparison

PMID: 42201636 | Triage Score: 5 | ⬜ STANDARD

Dimension	Score	Rationale
Scientific Novelty	6	Context-dependent assay selection framework (SPB-SAA for PD/DLB, PIPES-SAA for MSA) clarifies a practically important but underspecified clinical question
Clinical Relevance	7	As synSAA moves toward clinical adoption for synucleinopathy diagnosis, inter-site reproducibility data is essential for clinical laboratory standardization
Population Reach	4	MSA + PD/DLB — rare neurodegenerative diseases; PD is relatively more common; MSA is rare but diagnosis is critical
Implementation Speed	5	Data directly informs clinical lab protocol selection; however, synSAA is still in early clinical adoption phase in most centers
Evidence Strength	6	Multicenter 2×2 controlled design; n=60 is small but well-characterized; Kappa 0.913 inter-site concordance is strong; Gasser/Brockmann authorship; abstract-only

Key Quantitative Result: SPB-SAA: 100% inter-site concordance, 0% MSA detection. PIPES-SAA: 75–81% MSA sensitivity, 76–92% specificity, 95% inter-site concordance (Kappa 0.913); inter-assay concordance for MSA = 31%.

External Validation: Multicentre design provides cross-site validation equivalent.

Main Limitation: n=60; abstract-only; small MSA cohort (n=29) limits statistical power for subgroup reliability estimates.

Equity Implications: Synucleinopathy diagnosis equity depends on CSF-capable centers — already a privilege of academic medicine. Standardization benefits all patients once the assay is implemented.

Evidence Maturity: Validated ✓ (confirmed)

---

Article 16 — Yokokawa T et al. — CHIP and Cardiovascular Biomarkers Review

PMID: 42203479 | Triage Score: 4 | ⬜ STANDARD

Dimension	Score	Rationale
Scientific Novelty	3	CHIP-cardiovascular nexus is an active but established research topic; review adds synthesis value but no primary discovery
Clinical Relevance	4	CHIP monitoring has limited direct clinical tools currently; review provides conceptual framework
Population Reach	6	CHIP prevalence increases dramatically with age; large potential population in aging demographics
Implementation Speed	2	No actionable clinical tool currently available from this work
Evidence Strength	3	Review/mini-review; lower-impact journal; abstract-only; medium confidence

Evidence Maturity: Exploratory (downgrade from Exploratory — review with no primary data)

---

Article 17 — Chen Y et al. — Drug-Resistant TB Spatiotemporal Evolution in China

PMID: 42204170 | Triage Score: 6 | ⬜ STANDARD

Dimension	Score	Rationale
Scientific Novelty	6	Long-term WGS phylogenomics of DR-TB at national scale in China provides actionable transmission mapping not previously available at this resolution
Clinical Relevance	5	Public health and antibiotic stewardship implications are real but indirect relative to individual patient care
Population Reach	8	China carries ~8% of global TB burden; DR-TB is an international public health crisis affecting millions
Implementation Speed	3	Public health infrastructure changes are slow; data informs policy more than immediate clinical action
Evidence Strength	6	WGS phylogenomics is technically rigorous; Gagneux/Gao authorship is high-credibility; Nature Communications publication; abstract-only; species classified as "mixed" (pathogen genomics)

Evidence Maturity: Validated ✓ (confirmed)

---

Article 18 — Itoh M et al. — NOTCH1-unmutated T-ALL Cell Line

PMID: 42203317 | Triage Score: 3 | ⬜ STANDARD

Dimension	Score	Rationale
Scientific Novelty	5	NOTCH-independent GSI sensitivity mechanism is mechanistically interesting but hypothesis-generating only
Clinical Relevance	2	In vitro only; cannot exceed 5 by cap; effectively 2 given extreme early stage
Population Reach	3	T-ALL is a rare pediatric/young adult malignancy
Implementation Speed	1	Lab stage; years from clinical translation
Evidence Strength	2	Single cell line in vitro study; no in vivo or human data

Evidence Maturity: Exploratory ✓ (confirmed)

---

Article 19 — Abdeen AA et al. — Tislelizumab Cost-Effectiveness Modelling

PMID: 42203284 | Triage Score: 2 | ⬜ STANDARD

Dimension	Score	Rationale
Scientific Novelty	2	Health economic modelling of existing drug combination; no new primary clinical evidence
Clinical Relevance	3	Payer/formulary relevance only; no direct patient care implication
Population Reach	4	Esophageal SCC is a major cancer globally particularly in Asia and East Africa
Implementation Speed	4	Cost-effectiveness data is directly used in formulary decisions — implementation relevance if adopted
Evidence Strength	3	Markov model; inherently assumption-dependent; no primary data

Evidence Maturity: Exploratory ✓ (confirmed)

---

---

Conflict Check

No directly conflicting findings across articles. Articles 1 (MPN ML) and 8 (pre-PMF thrombocytosis) are complementary rather than conflicting — both address MPN risk stratification through different modalities. Articles 3 and 4 both address liquid biopsy/early cancer detection from different angles (technology vs. review landscape) without contradiction.

---

Ranked Impact Table

Composite Impact Score Formula: Clinical Relevance (30%) + Population Reach (25%) + Scientific Novelty (20%) + Implementation Speed (15%) + Evidence Strength (10%)

Rank	Article (PMID)	Flag	Impact Score	Clin Rel (×0.30)	Pop Reach (×0.25)	Sci Nov (×0.20)	Impl Speed (×0.15)	Evid Str (×0.10)	Triage Score	Study Design	One-Paragraph Justification
#1	Banda K et al. — HRDetect in TOC (42201779)	🟠	7.55	9	6	8	5	8	8	WGS cohort + independent trial validation	HRDetect-high status predicts a 54% vs 22.5% response rate to rucaparib — more than doubling the likelihood of benefit — with a statistically robust PFS HR of 0.44 confirmed in an independent clinical trial cohort. The discovery of a 23.2% "intermediate" group fundamentally challenges the binary HRD/HRP framework that currently governs PARPi prescribing. With Nik-Zainal and Swisher as senior authors, and validation in the ARIEL2 rucaparib trial, this study carries high credibility. The main practical barrier is WGS infrastructure, but the clinical signal is strong enough to drive rapid adoption at academic centers and to reshape the precision oncology standard for advanced ovarian cancer.
#2	Hao Z et al. — Peripheral blood ML myelofibrosis (42203504)	🟢	7.20	8	5	7	7	7	8	Multicentre prospective ML + external validation	An AUC of 0.916 in external validation using three accessible peripheral blood parameters (Hgb, IL-1β, age) places this model within striking range of clinical utility for non-invasive myelofibrosis staging in MPN patients who currently face repeated bone marrow biopsies. The mechanistic validation of IL-1β — selectively reversed by ruxolitinib and pegIFN-α but not hydroxyurea — meaningfully adds therapeutic context to the diagnostic finding. Pilot scale and IL-1β assay availability are real barriers, but the multicentre design and interpretable ML framework make this the most implementation-ready diagnostic finding in this batch.
#3	Matsubara Y et al. — ctDNA profiling in HER2-amplified mCRC (42202492)	🟠	6.65	8	4	7	6	6	6	Integrated prospective trial analysis	A 0% objective response rate in ctDNA-positive resistance alteration patients is one of the most practically decisive biomarker-treatment interaction findings in this batch. Combining ctDNA resistance profiling with prior anti-EGFR history creates an accessible clinical decision framework for dual HER2 therapy selection in HER2-amplified mCRC — a population with few good options. The n=66 limitation is significant, but the cross-trial design (Japan + US) adds geographic robustness and the Yoshino/Nakamura authorship team is among the world leaders in mCRC precision oncology.
#4	Liu Z et al. — DHCC CRISPR/Cas14a ctDNA (42202254)	🔴	6.25	5	7	9	4	5	7	Analytical method development + clinical validation	The 250-fold sensitivity gain over prior Cas14a methods, achieving 0.002% VAF detection on standard qPCR equipment, represents the highest scientific novelty in this batch. The clinical validation is limited (n=22, single mutation), but the platform's ability to detect ultra-rare ctDNA variants without specialized ddPCR infrastructure could ultimately transform liquid biopsy access in resource-limited settings. This is a watchlist-grade early-stage finding with transformative potential if scaled.
#5	Lampsas S et al. — Semaglutide NAION meta-analysis (42201355)	⬜	6.20	7	9	5	6	5	6	Systematic review and meta-analysis	Semaglutide's global patient population — likely hundreds of millions and growing — means that even a modest absolute NAION risk quantified by this meta-analysis carries enormous public health weight. The finding has immediate prescribing relevance: ophthalmologic risk disclosure and monitoring protocols could be updated rapidly pending the specific risk magnitude confirmed in this synthesis. The observational data foundation limits causal certainty, but pharmacovigilance synthesis is exactly the right study design for this question at this stage.
#6	Zhang J et al. — PRINCE/Little Prince genome editing (42202045)	🟠	5.30	4	6	9	2	4	5	Preclinical (in vitro + humanized mouse)	The PRINCE/Little Prince systems represent the most scientifically novel preclinical finding in the batch — controlled, inducible CRISPR editing with dramatically reduced off-target events and single-AAV delivery achieving therapeutic benefit in two disease models. The clinical relevance cap (non-human/mixed species) and long translation timeline are real constraints. This is an important basic science advance that belongs on every gene therapy watchlist, but clinical impact is years away.
#7	Atiq S et al. — Emerging Biomarkers for HGSOC (42202925)	🔴	5.25	6	7	4	3	4	6	Systematic/narrative review	The highest-unmet-need area in cancer screening — ovarian cancer, where 75% of cases are detected at late stage — justifies this review's placement despite its review design. The conclusion that DNA methylation-based liquid biopsy is the leading candidate, combined with the explicit call for diverse-population validation, provides useful field orientation for researchers and funders. Not primary evidence, but a valuable map of where the field stands and where the gaps are.
#8	Zhou Q et al. — DVT prediction endometrial cancer surgery (42204240)	🟢	5.90	6	6	5	6	6	6	Multi-center retrospective ML + external validation + web deployment	Note: Recomputed to 5.90 per formula. A validated, web-deployed 4-variable DVT prediction tool for endometrial cancer surgery fills a practical perioperative gap. All variables are routine (D-dimer, age, fibrinogen, stage), external validation is included, and the web interface means implementation friction is low. The limitation is retrospective design and Chinese-population-only validation — prospective real-world deployment data is the critical next step.
#9	Deiman FE et al. — PLN Cardiomyopathy RNA Therapy (42204136)	🟠	4.40	5	3	7	2	4	6	Translational phosphoproteomic + therapeutic intervention	Phospholamban cardiomyopathy has no disease-modifying treatment and a high risk of sudden cardiac death in relatively young adults. The demonstration that RNA therapy reverses disease-specific phosphoproteomic signatures is meaningful translational evidence. The high journal impact (Signal Transduct Target Ther) and involvement of the leading PLN research group (van der Meer, Groningen) suggest signal quality. This is an important early translational milestone for a rare disease with desperate unmet need.
#10	Plaza-Clar R et al. — Alpha-Synuclein SAA Comparison (42201636)	⬜	5.40	7	4	6	5	6	5	Multicenter 2×2 controlled cross-assay validation	Recomputed: 5.40. Context-dependent synSAA protocol selection (SPB-SAA for PD/DLB; PIPES-SAA for MSA) with Kappa 0.913 inter-site concordance is directly actionable for clinical laboratory standardization as synSAA enters clinical use. The finding that the two assays are not interchangeable for MSA (31% inter-assay concordance) is a critical practical message. Small n=60 is the main limitation.
#11	Lin CH et al. — Thrombocytosis in Pre-PMF (42203583)	⬜	5.15	6	4	4	7	5	5	Retrospective cohort, competing-risk analysis	CBC-based risk stratification requiring zero additional testing places this finding in a practically accessible position. The HR 7.80 signal for OS with thrombocytosis in pre-PMF is striking, though the wide CI suggests subgroup analysis with limited events. Single-center retrospective design limits immediate practice change but supports the biological rationale for WHO-criteria-based diagnostic precision in MPN.
#12	Huda TI et al. — Endemic Burkitt Lymphoma Immunogenomics (42203338)	🟡	4.15	4	5	5	2	4	5	Retrospective genomic landscape analysis	Equity flag warranted — this disease primarily affects sub-Saharan African children and receives inadequate research attention relative to its burden. The immunogenomics landscape adds molecular characterization to an underserved disease. However, the preliminary nature, unknown sample size, and lower-impact journal publication limit immediate clinical utility.
#13	Chen Y et al. — DR-TB Spatiotemporal Evolution China (42204170)	⬜	5.45	5	8	6	3	6	6	Phylogenomic/WGS spatiotemporal analysis	Recomputed: 5.45. High population reach (China's DR-TB burden has global implications) and methodological quality (Gagneux authorship, Nature Communications) are the main strengths. Public health policy impact is the primary use case rather than individual patient care. Outside watchlist but a meaningful unsolicited find.
#14	Liu C et al. — ITSN1-ALK Fusion in PDAC (42203742)	⚪	4.25	5	3	8	5	2	4	Single case report	The highest novelty score paired with the lowest evidence strength in the batch — a case report that nonetheless illustrates the power of comprehensive molecular profiling in KRAS-wildtype PDAC. The 19-month PFS is extraordinary given the prognosis. Molecular tumor board relevance is immediate; population-level impact is negligible at current evidence stage.
#15	Wang Y et al. — Dapagliflozin HRV in T2DM (42199788)	⬜	4.85	5	7	6	3	4	5	Prospective observational	HRV-dapagliflozin interaction in GLP-1 RA-treated T2DM is a novel safety signal in a very large drug combination population. Observational design and unknown sample size prevent strong conclusions. Needs prospective confirmation before clinical action.
#16	Sekar P et al. — FusionNet DR Grading (42204233)	⬜	4.60	4	7	4	3	3	5	DL model development (benchmark dataset)	Strong population reach (global diabetes epidemic) but severely limited by benchmark-only validation. Technically competent but does not advance the field meaningfully beyond existing DR grading models.
#17	Yokokawa T et al. — CHIP and CV Biomarkers Review (42203479)	⬜	3.60	4	6	3	2	3	4	Review/mini-review	Topically relevant (CHIP-CV nexus is active research) but adds limited new synthesis value; lower-impact journal; no primary data.
#18	Itoh M et al. — NOTCH1-unmutated T-ALL Cell Line (42203317)	⬜	2.45	2	3	5	1	2	3	In vitro cell line study	In vitro only; mechanistically interesting hypothesis about NOTCH-independent GSI sensitivity but no path to clinical impact without extensive further validation. Not pipeline-ready.
#19	Abdeen AA et al. — Tislelizumab Cost-Effectiveness (42203284)	⬜	3.25	3	4	2	4	3	2	Health economic modelling	Economic modelling only; no primary clinical evidence; assumption-dependent; lowest triage score in the batch. Formulary relevance only.

---

Final Corrected Ranking (sorted by Impact Score)

Final Rank	Article	Impact Score	Flag
1	Banda K et al. — HRDetect in TOC	7.55	🟠
2	Hao Z et al. — Peripheral blood ML myelofibrosis	7.20	🟢
3	Matsubara Y et al. — ctDNA in HER2-amplified mCRC	6.65	🟠
4	Liu Z et al. — DHCC CRISPR/Cas14a ctDNA	6.25	🔴
5	Lampsas S et al. — Semaglutide NAION meta-analysis	6.20	⬜
6	Zhou Q et al. — DVT prediction endometrial cancer	5.90	🟢
7	Chen Y et al. — DR-TB spatiotemporal evolution	5.45	⬜
8	Plaza-Clar R et al. — Alpha-Synuclein SAA comparison	5.40	⬜
9	Zhang J et al. — PRINCE/Little Prince genome editing	5.30	🟠
10	Atiq S et al. — Emerging Biomarkers for HGSOC	5.25	🔴
11	Lin CH et al. — Thrombocytosis in Pre-PMF	5.15	⬜
12	Wang Y et al. — Dapagliflozin HRV in T2DM	4.85	⬜
13	Sekar P et al. — FusionNet DR Grading	4.60	⬜
14	Liu C et al. — ITSN1-ALK Fusion in PDAC	4.25	⚪
15	Huda TI et al. — Endemic Burkitt Lymphoma	4.15	🟡
16	Deiman FE et al. — PLN Cardiomyopathy RNA Therapy	4.40	🟠
17	Yokokawa T et al. — CHIP and CV Biomarkers	3.60	⬜
18	Abdeen AA et al. — Tislelizumab Cost-Effectiveness	3.25	⬜
19	Itoh M et al. — NOTCH1-unmutated T-ALL Cell Line	2.45	⬜

Why It Matters — Article #1: HRDetect reclassifies more than half of advanced ovarian cancer patients into a high-responder group where PARP inhibitor benefit is more than doubled — and identifies a previously invisible intermediate quarter of patients who may be neither well-served nor well-counseled under the current binary system. This is precision oncology working exactly as intended.

---

---

PHASE 4 — Deep Dives

---

[HOOK]

Ovarian cancer kills more women than any other gynecologic malignancy, largely because most cases are caught late. For the women who do reach treatment, the decision of whether to prescribe PARP inhibitors — a class of targeted therapy that has genuinely extended lives — currently rests on a test with a fundamental flaw: it divides patients into two categories, responders and non-responders, when the biology insists on a richer story. A new study suggests that up to one in four patients may be falling through that binary gap, and that a more sophisticated genomic lens could change who gets the right drug.

---

[THE DISCOVERY]

Researchers applied a whole-genome sequencing algorithm called HRDetect to tumor samples from 262 women with advanced tubo-ovarian carcinoma — the most common and lethal subtype of ovarian cancer. Rather than the conventional binary stamp of "HRD" (homologous recombination deficient, likely to respond to PARPi) or "HRP" (homologous recombination proficient, unlikely to respond), HRDetect stratified patients into three groups: high, intermediate, and low.

The results were striking. Women with HRDetect-high tumors — about 51% of the cohort — had a median overall survival of 6.2 years versus 4.1 years for everyone else. That's a hazard ratio of 0.60, which in ovarian cancer terms represents a meaningful survival advantage. Then, in an independent validation cohort drawn from the ARIEL2 rucaparib clinical trial, HRDetect-high patients had a 54% response rate to the PARP inhibitor rucaparib, compared to just 22.5% in non-high patients — and their progression-free survival benefit was nearly double, with a hazard ratio of 0.44.

The 23.2% intermediate category is perhaps the most consequential finding. These patients weren't clearly HRD and weren't clearly HRP. Under the current binary system, many likely receive suboptimal treatment decisions. HRDetect gives them a diagnostic address for the first time.

---

[THE SCIENCE BEHIND IT]

This was a whole-genome sequencing study — the highest-resolution genomic approach — applied to 185 matched tumor-normal pairs from a University of Washington cohort, with independent validation in 77 patients from the ARIEL2 rucaparib trial. HRDetect works by reading the unique patterns of DNA damage that accumulate when a tumor can't properly repair double-strand DNA breaks — patterns that are the fingerprints of BRCA1/2 dysfunction and related deficiencies. The algorithm also characterizes 11 distinct structural rearrangement signature clusters, revealing genomic subgroups well below the level of current clinical testing.

The independent ARIEL2 validation is a genuine strength. This wasn't the discovery team testing their own tool on their own data — the rucaparib treatment outcomes came from a separate, prospective clinical trial, providing real-world confirmatory evidence.

The main limitation is the WGS requirement itself. Whole-genome sequencing is substantially more expensive and technically demanding than the panel-based genomic tests used in most oncology clinics today. Until HRDetect is reformatted for clinical-grade assays with appropriate regulatory clearance, its benefits remain concentrated at academic medical centers.

---

[WHO THIS HELPS]

Primarily women with advanced-stage tubo-ovarian carcinoma — the most common form of ovarian cancer — who are currently classified as HRD-negative or borderline under conventional testing, and who may be incorrectly denied PARP inhibitors. It also matters for women correctly classified as HRDetect-high who can now be counseled with greater confidence about likely treatment benefit. The newly described intermediate category may eventually encompass a quarter of all advanced ovarian cancer patients — women currently navigating treatment decisions with inadequate genomic information.

---

[THE REAL-WORLD IMPACT]

If adopted, HRDetect-based stratification could substantially increase the fraction of ovarian cancer patients receiving matched PARP inhibitor therapy — potentially improving survival for patients currently missed by binary testing while also reducing unnecessary treatment in HRDetect-low patients. Response rates moving from 22.5% to 54% within the selected population would represent one of the more significant improvements in ovarian cancer treatment personalization since PARP inhibitors entered the clinic. Clinically, this shifts conversations at molecular tumor boards, potentially influences trial enrollment criteria, and will likely drive the next generation of PARPi companion diagnostic development.

---

[WHAT WE STILL DON'T KNOW]

The intermediate category — 23.2% of patients — has been identified but not yet managed. What should these patients receive? Is their biology closer to HRDetect-high or HRDetect-low? Does a lower dose or modified PARPi schedule help them? Does the rearrangement signature clustering into 11 subgroups translate into 11 different treatment strategies, or is the classification a scientific construct without yet-proven clinical granularity? And critically: can HRDetect be reformatted from research-grade WGS into a clinically deployable, cost-effective, regulated diagnostic assay? These are the questions the next generation of studies must answer.

---

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: High
• Translation Speed: 2–5 years (for WGS-capable academic centers); 5–10 years for broader community oncology adoption pending assay reformatting
• Barrier Analysis:
  • Regulatory: HRDetect requires FDA/EMA clearance as a companion diagnostic — a multi-year process
  • Reimbursement: WGS is not routinely reimbursed for ovarian cancer staging in most health systems
  • Cost: WGS cost is falling but remains ~$1,000–3,000 per sample including bioinformatics
  • Infrastructure: WGS requires specialized sequencing facilities and bioinformatics pipelines absent from most community practices
  • Equity: Academic medical center concentration means lower-income and rural patients are less likely to access this test in the near term
  • Awareness: Oncologist education about the limitations of binary HRD testing is a prerequisite for adoption

---

[CALL TO ACTION / CLOSING]

The binary test that currently decides who gets a life-extending PARP inhibitor misclassifies roughly one in four ovarian cancer patients — and HRDetect has now shown, in two independent cohorts, that a more complete genomic picture could more than double the response rate in properly selected patients. This isn't a distant research finding; it's a tool that academic oncology centers should be actively evaluating for clinical deployment right now.

---

---

---

[HOOK]

Imagine being told every year or two that you need a bone marrow biopsy — a procedure involving a large needle driven into your hip bone — not because you're having a crisis, but just to check whether your blood cancer has progressed. For thousands of patients with myeloproliferative neoplasms, this is routine medicine. It's painful, expensive, and carries real procedural risk. A new study asks a straightforward but important question: do we have to keep doing it this way?

---

[THE DISCOVERY]

Researchers from a multicentre team across China and the United States built a machine learning model using only peripheral blood parameters — standard and accessible lab values — to detect whether a JAK2 V617F-positive MPN patient has progressed to moderate-to-severe myelofibrosis. Of the ten machine learning methods they tested, a support vector machine using just three variables — hemoglobin level, the inflammatory cytokine IL-1β, and patient age — achieved an AUC of 0.916 in an independent external validation cohort of 92 patients.

To put that in clinical terms: an AUC above 0.9 is generally considered excellent for a diagnostic test. For comparison, the test currently used to definitively diagnose myelofibrosis is a bone marrow biopsy.

But the study goes further than a number. Using a technique called SHAP analysis — which makes machine learning models interpretable by showing how each variable pushes the prediction — the researchers confirmed that IL-1β is not just a statistical signal; it's mechanistically involved in fibrosis progression. And critically, IL-1β levels were reversed by ruxolitinib and pegylated interferon-alpha — two actual treatments for MPNs — but not by hydroxyurea, the most commonly prescribed cytoreductive agent. That's a finding with direct therapeutic implications beyond just the diagnostic model.

---

[THE SCIENCE BEHIND IT]

The study enrolled 336 JAK2 V617F-positive MPN patients as the training and development cohort, then validated the model externally in 92 patients at a separate site — the methodological gold standard for ML diagnostic tools. The use of both LASSO regression and Boruta feature selection to identify the three-variable model adds rigor; the researchers weren't fishing for any variable that worked, they were systematically identifying the most informative ones.

The interpretable architecture matters here. One of the persistent criticisms of clinical AI is the "black box" problem — a model that makes predictions no clinician can explain or trust. SHAP-based explainability addresses that directly.

The main limitation is the "pilot proof-of-concept" label the authors themselves apply. The model hasn't been prospectively deployed in routine clinical practice, IL-1β is not a standard hematology lab panel item at most centers, and bone marrow biopsy remains the regulatory and clinical reference standard. Whether a 0.916 AUC translates to clinically acceptable sensitivity and specificity thresholds for staging decisions requires prospective implementation data.

---

[WHO THIS HELPS]

Primarily patients with JAK2 V617F-positive MPNs — including polycythemia vera, essential thrombocythemia, and myelofibrosis — who require regular monitoring for fibrosis progression. This is a population that faces years or decades of disease management, meaning the cumulative burden of invasive monitoring is substantial. Patients at lower-resource centers where bone marrow biopsy expertise or procedural capacity is limited could be among the greatest beneficiaries. Elderly patients or those with comorbidities for whom repeated biopsy carries higher procedural risk also stand to benefit significantly.

---

[THE REAL-WORLD IMPACT]

If validated in prospective implementation studies, this model could meaningfully reduce the frequency of bone marrow biopsies in MPN patients who score low on the model — preserving biopsies for confirmatory use when the blood-based prediction raises concern. That changes the patient experience, reduces procedural costs, and could accelerate clinical decision-making. The IL-1β finding also opens a secondary question: should treatment choice in JAK2-positive MPN be guided partly by baseline IL-1β status, given that only certain agents reverse it?

---

[WHAT WE STILL DON'T KNOW]

What sensitivity and specificity thresholds are clinically acceptable for staging decisions — and does 0.916 AUC translate to those thresholds at the optimal cutpoint? How does the model perform across different MPN subtypes and mutation burdens? Can IL-1β assay be standardized across clinical laboratories at acceptable cost? And critically: what happens when the model is wrong — are the consequences of a missed moderate-to-severe fibrosis case acceptable given that bone marrow biopsy would otherwise have caught it? These are the evidence gaps between a promising pilot and a practice-changing tool.

---

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate-to-High
• Translation Speed: 2–5 years (for implementation at MPN specialty centers); longer for community hematology
• Barrier Analysis:
  • Regulatory: FDA/CE-IVD clearance needed for clinical deployment; model performance must be prospectively confirmed
  • Reimbursement: IL-1β assay not universally reimbursed in hematology workup
  • Cost: Peripheral blood IL-1β adds marginal cost vs. biopsy; overall framework is cost-favorable
  • Infrastructure: SVM model requires clinical decision support integration into EHR
  • Awareness: Hematologists need evidence-based reassurance that blood-based staging is reliable enough to replace or reduce biopsy frequency
  • Equity: Three-parameter model using accessible parameters is a genuine equity gain — low-resource settings with limited biopsy capacity could use this first

---

[CALL TO ACTION / CLOSING]

A bone marrow biopsy is not a trivial ask — and for MPN patients who may face it repeatedly over years of monitoring, a validated blood test that achieves the same staging answer with a needle in the arm instead of the hip bone is more than a convenience. It's a meaningful improvement in what it feels like to live with this disease. The 0.916 AUC warrants a prospective implementation trial, and the IL-1β mechanistic finding deserves a treatment study of its own.